Precision oncology uses information about a tumour's molecular and biological characteristics to help guide cancer treatment. Genetic or biomarker testing may identify changes that influence treatment selection. Not every cancer has an actionable biomarker or an available targeted medicine.
Chemotherapy involves medicines that destroy or inhibit rapidly dividing cancer cells. It may be used alone or alongside surgery, radiation or other systemic treatments. Drug selection and scheduling depend on cancer type, stage and the patient's health.
Targeted therapies act on particular molecules or pathways involved in cancer growth. Their use often depends on biomarker testing. Treatment options vary by tumour type, and not every patient is eligible for targeted therapy.
Immunotherapy aims to help the immune system recognise or attack cancer cells. Certain medicines are used for selected cancers depending on clinical characteristics and biomarker findings. Treatment requires monitoring for immune-related side effects that can affect different organs.
Cancer genomic profiling examines selected genetic alterations within tumour tissue or other samples. Results may help identify potentially useful targeted treatments, clinical trial options or other treatment considerations. Testing is chosen according to the cancer diagnosis and clinical need.
Medical treatment for breast cancer may include chemotherapy, hormone therapy, targeted medicines or immunotherapy according to tumour characteristics. Treatment planning considers cancer stage, receptor status, HER2 status, previous treatment and the patient's overall condition.
Medical oncology management of lung cancer depends on tumour type, stage and molecular findings. Treatment may involve chemotherapy, targeted therapy or immunotherapy. A multidisciplinary team may also assess whether surgery or radiation is appropriate.
Gastrointestinal cancers can affect organs such as the stomach, colon, rectum and pancreas. Systemic treatment depends on the site and stage of disease, molecular findings and patient fitness. Care often involves coordination with surgical and radiation oncology teams.
Hemato-oncology involves the evaluation and treatment of cancers affecting blood-forming tissues and the lymphatic system. Conditions may include leukaemia, lymphoma and myeloma. Management depends on specialist diagnostic testing, disease classification and individual treatment requirements.
Cancer treatment planning involves reviewing pathology, imaging, disease stage, molecular findings and the patient's medical condition. The resulting plan may combine systemic medicines with surgery, radiation or supportive care as clinically appropriate.
Supportive oncology focuses on managing symptoms and complications related to cancer or its treatment. Care may address nausea, fatigue, pain, nutrition, infection risk and emotional concerns. Supportive treatment can be provided alongside active anticancer therapy.